SE9301830D0
(sv)
*
|
1993-05-28 |
1993-05-28 |
Ab Astra |
New compounds
|
US6875872B1
(en)
|
1993-05-28 |
2005-04-05 |
Astrazeneca |
Compounds
|
SE9402431D0
(sv)
*
|
1994-07-08 |
1994-07-08 |
Astra Ab |
New tablet formulation
|
ATE414509T1
(de)
*
|
1994-07-08 |
2008-12-15 |
Astrazeneca Ab |
Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform
|
SE9500422D0
(sv)
*
|
1995-02-06 |
1995-02-06 |
Astra Ab |
New oral pharmaceutical dosage forms
|
SE9500478D0
(sv)
*
|
1995-02-09 |
1995-02-09 |
Astra Ab |
New pharmaceutical formulation and process
|
US6279736B1
(en)
|
1995-04-19 |
2001-08-28 |
Capitol Specialty Plastics, Inc. |
Barrier pack having an absorbing agent applied to the interior of the pack
|
HU227566B1
(en)
*
|
1995-09-21 |
2011-08-29 |
Pharma Pass Llc |
Acid-labile pharmaceutical composition containing omeprazole and process for its preparation
|
US6699885B2
(en)
|
1996-01-04 |
2004-03-02 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and methods of using same
|
US6489346B1
(en)
*
|
1996-01-04 |
2002-12-03 |
The Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
US5840737A
(en)
|
1996-01-04 |
1998-11-24 |
The Curators Of The University Of Missouri |
Omeprazole solution and method for using same
|
US6645988B2
(en)
|
1996-01-04 |
2003-11-11 |
Curators Of The University Of Missouri |
Substituted benzimidazole dosage forms and method of using same
|
SE9600071D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral formulation of two active ingredients I
|
SE9600070D0
(sv)
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral pharmaceutical dosage forms
|
SE9600072D0
(sv)
*
|
1996-01-08 |
1996-01-08 |
Astra Ab |
New oral formulation of two active ingredients II
|
SE512835C2
(sv)
*
|
1996-01-08 |
2000-05-22 |
Astrazeneca Ab |
Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
|
SE508669C2
(sv)
*
|
1996-04-26 |
1998-10-26 |
Astra Ab |
Nytt förfarande
|
SE9602442D0
(sv)
*
|
1996-06-20 |
1996-06-20 |
Astra Ab |
Administration of pharmaceuticals
|
US6623759B2
(en)
*
|
1996-06-28 |
2003-09-23 |
Astrazeneca Ab |
Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
|
DE19637082A1
(de)
*
|
1996-09-12 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Schnellzerfallende Pellets
|
WO1998019668A1
(en)
*
|
1996-11-06 |
1998-05-14 |
Sharmatek, Inc. |
Delayed delivery system for acid-sensitive drugs
|
SE510666C2
(sv)
*
|
1996-12-20 |
1999-06-14 |
Astra Ab |
Nya Kristallmodifikationer
|
ID21806A
(id)
*
|
1997-01-06 |
1999-07-29 |
Pfizer |
Bentuk penakaran farmasi yang secara cepat dilepaskan dan yang menutup rasa
|
AU731186B2
(en)
*
|
1997-03-13 |
2001-03-29 |
Hexal Ag |
Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
|
SE9702000D0
(sv)
*
|
1997-05-28 |
1997-05-28 |
Astra Ab |
New pharmaceutical formulation
|
US6747155B2
(en)
|
1997-05-30 |
2004-06-08 |
Astrazeneca Ab |
Process
|
SE510650C2
(sv)
|
1997-05-30 |
1999-06-14 |
Astra Ab |
Ny förening
|
SE510643C2
(sv)
|
1997-06-27 |
1999-06-14 |
Astra Ab |
Termodynamiskt stabil omeprazol natrium form B
|
SE9702533D0
(sv)
|
1997-07-01 |
1997-07-01 |
Astra Ab |
New oral formulation
|
US6096340A
(en)
|
1997-11-14 |
2000-08-01 |
Andrx Pharmaceuticals, Inc. |
Omeprazole formulation
|
US6174548B1
(en)
|
1998-08-28 |
2001-01-16 |
Andrx Pharmaceuticals, Inc. |
Omeprazole formulation
|
US6221402B1
(en)
|
1997-11-20 |
2001-04-24 |
Pfizer Inc. |
Rapidly releasing and taste-masking pharmaceutical dosage form
|
DK1037607T3
(da)
*
|
1997-12-08 |
2004-06-21 |
Altana Pharma Ag |
Hidtil ukendt suppositoriumsform, der omfatter en syrelabil aktiv forbindelse
|
SE9704870D0
(sv)
*
|
1997-12-22 |
1997-12-22 |
Astra Ab |
New pharmaceutical formulation I
|
SE9704869D0
(sv)
*
|
1997-12-22 |
1997-12-22 |
Astra Ab |
New pharmaceutical formulaton II
|
CN1141097C
(zh)
|
1998-04-20 |
2004-03-10 |
卫材株式会社 |
含有稳定化的苯并咪唑类化合物的组合物
|
CN1195500C
(zh)
|
1998-05-18 |
2005-04-06 |
武田药品工业株式会社 |
可口腔崩解的片剂
|
ZA9810765B
(en)
*
|
1998-05-28 |
1999-08-06 |
Ranbaxy Lab Ltd |
Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
|
US6733778B1
(en)
|
1999-08-27 |
2004-05-11 |
Andrx Pharmaceuticals, Inc. |
Omeprazole formulation
|
SE9803772D0
(sv)
*
|
1998-11-05 |
1998-11-05 |
Astra Ab |
Pharmaceutical formulation
|
IL142703A
(en)
*
|
1998-11-10 |
2006-04-10 |
Astrazeneca Ab |
Crystalline form of omeprazole
|
JP3926936B2
(ja)
*
|
1998-11-16 |
2007-06-06 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホキシド誘導体・アセトン錯体およびその製造法
|
SE9900274D0
(sv)
|
1999-01-28 |
1999-01-28 |
Astra Ab |
New compound
|
DK1187601T3
(da)
|
1999-06-07 |
2005-11-21 |
Altana Pharma Ag |
Hidtil ukendt præparat og administrationsform som omfatter en syrelabil protonpumpeinhibitor
|
IL130602A0
(en)
*
|
1999-06-22 |
2000-06-01 |
Dexcel Ltd |
Stable benzimidazole formulation
|
US6245913B1
(en)
|
1999-06-30 |
2001-06-12 |
Wockhardt Europe Limited |
Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
|
US6312712B1
(en)
|
1999-08-26 |
2001-11-06 |
Robert R. Whittle |
Method of improving bioavailability
|
US6262085B1
(en)
|
1999-08-26 |
2001-07-17 |
Robert R. Whittle |
Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6268385B1
(en)
|
1999-08-26 |
2001-07-31 |
Robert R. Whittle |
Dry blend pharmaceutical formulations
|
US6369087B1
(en)
|
1999-08-26 |
2002-04-09 |
Robert R. Whittle |
Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
|
US6262086B1
(en)
|
1999-08-26 |
2001-07-17 |
Robert R. Whittle |
Pharmaceutical unit dosage form
|
US6780880B1
(en)
*
|
1999-08-26 |
2004-08-24 |
Robert R. Whittle |
FT-Raman spectroscopic measurement
|
US6312723B1
(en)
|
1999-08-26 |
2001-11-06 |
Robert R. Whittle |
Pharmaceutical unit dosage form
|
US6316020B1
(en)
|
1999-08-26 |
2001-11-13 |
Robert R. Whittle |
Pharmaceutical formulations
|
US6326384B1
(en)
|
1999-08-26 |
2001-12-04 |
Robert R. Whittle |
Dry blend pharmaceutical unit dosage form
|
SE0100823D0
(sv)
*
|
2001-03-09 |
2001-03-09 |
Astrazeneca Ab |
Method I to obtain microparticles
|
ES2168043B1
(es)
|
1999-09-13 |
2003-04-01 |
Esteve Labor Dr |
Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
|
PT1222922E
(pt)
|
1999-10-20 |
2007-09-12 |
Eisai R&D Man Co Ltd |
Método para estabilizar compostos de benzimidazole.
|
CA2290893C
(en)
|
1999-11-16 |
2007-05-01 |
Bernard Charles Sherman |
Magnesium omeprazole
|
DK1108425T3
(da)
*
|
1999-12-16 |
2005-09-26 |
Medinfar Produtos Farmaceutico |
Nye, stabile flerenhedspræparater, der indeholder substituerede benzimidazoler
|
SE0000774D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
New formulation
|
US6544556B1
(en)
|
2000-09-11 |
2003-04-08 |
Andrx Corporation |
Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
|
BR0115986A
(pt)
|
2000-12-07 |
2003-12-23 |
Altana Pharma Ag |
Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos
|
US20020192299A1
(en)
*
|
2000-12-28 |
2002-12-19 |
Rajneesh Taneja |
Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
|
SE0100822D0
(sv)
*
|
2001-03-09 |
2001-03-09 |
Astrazeneca Ab |
Method II to obtain microparticles
|
CA2448927C
(en)
*
|
2001-05-30 |
2011-08-09 |
Euro-Celtique, S.A. |
Pharmaceutical composition
|
US8206741B2
(en)
|
2001-06-01 |
2012-06-26 |
Pozen Inc. |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
CA2453290A1
(en)
*
|
2001-07-16 |
2003-01-30 |
Astrazeneca Ab |
Pharmaceutical formulation comprising a proton pump inhibitor and antacids
|
SE0102993D0
(sv)
|
2001-09-07 |
2001-09-07 |
Astrazeneca Ab |
New self emulsifying drug delivery system
|
MXPA04002973A
(es)
|
2001-09-28 |
2005-06-20 |
Johnson & Johnson |
Formas de dosis de liberacion modificada.
|
ES2198195B1
(es)
*
|
2001-12-18 |
2004-10-01 |
Laboratorios Del Dr. Esteve, S.A. |
Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
|
US20040006111A1
(en)
*
|
2002-01-25 |
2004-01-08 |
Kenneth Widder |
Transmucosal delivery of proton pump inhibitors
|
CA2474246C
(en)
|
2002-03-05 |
2010-06-29 |
Astrazeneca Ab |
Alkylammonium salts of omeprazole and esomeprazole
|
US20040082618A1
(en)
*
|
2002-07-03 |
2004-04-29 |
Rajneesh Taneja |
Liquid dosage forms of acid labile drugs
|
ES2299710T3
(es)
*
|
2002-08-02 |
2008-06-01 |
Ratiopharm Gmbh |
Preparacion farmaceutica que contiene un compuesto de bencimidazol mezclado con celulosa microcristalina y un metodo para su preparacion.
|
MY148805A
(en)
*
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
AU2003286836A1
(en)
*
|
2002-10-31 |
2004-06-07 |
Supergen, Inc. |
Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
|
US20040242642A1
(en)
*
|
2002-11-18 |
2004-12-02 |
Dr. Reddy's Laboratories Limited |
Crystalline esomeprazole compounds and process for the preparation thereof
|
US9107804B2
(en)
|
2002-12-10 |
2015-08-18 |
Nortec Development Associates, Inc. |
Method of preparing biologically active formulations
|
US20070243251A1
(en)
*
|
2002-12-20 |
2007-10-18 |
Rajneesh Taneja |
Dosage Forms Containing A PPI, NSAID, and Buffer
|
US20040121004A1
(en)
*
|
2002-12-20 |
2004-06-24 |
Rajneesh Taneja |
Dosage forms containing a PPI, NSAID, and buffer
|
US20040166162A1
(en)
*
|
2003-01-24 |
2004-08-26 |
Robert Niecestro |
Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
|
US20040185119A1
(en)
*
|
2003-02-26 |
2004-09-23 |
Theuer Richard C. |
Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
|
PE20050150A1
(es)
|
2003-05-08 |
2005-03-22 |
Altana Pharma Ag |
Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
|
CL2004000983A1
(es)
|
2003-05-08 |
2005-03-04 |
Altana Pharma Ag |
Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
|
EP2112920B1
(en)
|
2003-06-26 |
2018-07-25 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
US20070053981A1
(en)
*
|
2003-07-11 |
2007-03-08 |
Eva Blychert |
Solid composition comprising a proton pump inhibitor
|
US8993599B2
(en)
|
2003-07-18 |
2015-03-31 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
US20050043359A1
(en)
*
|
2003-08-20 |
2005-02-24 |
The Procter & Gamble Company |
Kit for treatment of upper gastrointestinal tract conditions
|
US20050232992A1
(en)
*
|
2003-09-03 |
2005-10-20 |
Agi Therapeutics Limited |
Proton pump inhibitor formulations, and methods of preparing and using such formulations
|
TWI372066B
(en)
|
2003-10-01 |
2012-09-11 |
Wyeth Corp |
Pantoprazole multiparticulate formulations
|
WO2005046634A2
(de)
*
|
2003-11-14 |
2005-05-26 |
Siegfried Generics International Ag |
Magensaftresistente verabreichungsform
|
US8906940B2
(en)
|
2004-05-25 |
2014-12-09 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
US8815916B2
(en)
|
2004-05-25 |
2014-08-26 |
Santarus, Inc. |
Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
|
US20070224269A1
(en)
*
|
2004-06-10 |
2007-09-27 |
Rubino Orapin P |
Controlled Release Pharmaceutical Formulation
|
JP2008502740A
(ja)
*
|
2004-06-15 |
2008-01-31 |
テバ ファーマシューティカル インダストリーズ リミティド |
ベンズイミダゾール化合物の安定医薬製剤
|
JP5563735B2
(ja)
|
2004-06-16 |
2014-07-30 |
タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド |
Ppi多回剤形
|
US20050281876A1
(en)
|
2004-06-18 |
2005-12-22 |
Shun-Por Li |
Solid dosage form for acid-labile active ingredient
|
KR100875299B1
(ko)
*
|
2004-06-29 |
2008-12-23 |
니코메드 덴마크 에이피에스 |
비수용성 약물의 속방성 약학 조성물 제조 방법 및 상기방법에 의하여 얻어지는 약학 조성물
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
ES2246149B1
(es)
*
|
2004-07-02 |
2007-06-01 |
Esteve Quimica, S.A. |
Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
|
EP1621187A1
(en)
*
|
2004-07-26 |
2006-02-01 |
AstraZeneca AB |
Pharmaceutical multiparticulate tablet formulations and process for their preparation
|
US20060024362A1
(en)
|
2004-07-29 |
2006-02-02 |
Pawan Seth |
Composition comprising a benzimidazole and process for its manufacture
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US8715724B2
(en)
*
|
2004-10-29 |
2014-05-06 |
Mayne Pharma International Pty Ltd |
Tabletting process
|
GB0427455D0
(en)
*
|
2004-12-15 |
2005-01-19 |
Jagotec Ag |
Dosage forms
|
EP1830822A1
(en)
*
|
2004-12-24 |
2007-09-12 |
LEK Pharmaceuticals D.D. |
Stable pharmaceutical composition comprising an active substance in the form of solid solution
|
US8673352B2
(en)
|
2005-04-15 |
2014-03-18 |
Mcneil-Ppc, Inc. |
Modified release dosage form
|
EP1912629A4
(en)
*
|
2005-07-08 |
2012-09-12 |
Univ Arkansas |
ASYMMETRIC COATING COMPRESSOR
|
ES2278511B1
(es)
*
|
2005-07-28 |
2008-06-16 |
Laboratorios Almirall S.A. |
Comprimidos con perfil de disolucion mejorado.
|
US20060165776A1
(en)
*
|
2005-08-31 |
2006-07-27 |
Ramesh Sesha |
Antidepressant oral pharmaceutical compositions
|
US9440003B2
(en)
*
|
2005-11-04 |
2016-09-13 |
Boston Scientific Scimed, Inc. |
Medical devices having particle-containing regions with diamond-like coatings
|
AR057181A1
(es)
*
|
2005-11-30 |
2007-11-21 |
Astra Ab |
Nueva forma de dosificacion de combinacion
|
CA2631919A1
(en)
|
2005-12-05 |
2007-06-14 |
Astrazeneca Ab |
New process for the preparation of esomeprazole non-salt form
|
US20070141151A1
(en)
*
|
2005-12-20 |
2007-06-21 |
Silver David I |
Lansoprazole orally disintegrating tablets
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US9561188B2
(en)
|
2006-04-03 |
2017-02-07 |
Intellipharmaceutics Corporation |
Controlled release delivery device comprising an organosol coat
|
SG170826A1
(en)
|
2006-04-04 |
2011-05-30 |
Kg Acquisition Llc |
Oral dosage forms including an antiplatelet agent and an acid inhibitor
|
WO2007122478A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Themis Laboratories Private Limited |
Multiple unit compositions
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US9023400B2
(en)
*
|
2006-05-24 |
2015-05-05 |
Flamel Technologies |
Prolonged-release multimicroparticulate oral pharmaceutical form
|
JP2009538901A
(ja)
*
|
2006-06-01 |
2009-11-12 |
デクセル ファーマ テクノロジーズ エルティーディー. |
複式ユニット製薬的製剤
|
US7713549B2
(en)
*
|
2006-06-30 |
2010-05-11 |
Board Of Trustees Of The University Of Arkansas |
Extended release perforated tablet
|
BRPI0717613A2
(pt)
*
|
2006-10-17 |
2013-10-22 |
Ranbaxy Lab Ltd |
Composição em comprimido de múltiplas unidades, processo para o preparo do mesmo e método para inibir a secreção de ácido gástrico
|
US20080103169A1
(en)
|
2006-10-27 |
2008-05-01 |
The Curators Of The University Of Missouri |
Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
|
US8352042B2
(en)
*
|
2006-11-28 |
2013-01-08 |
The Alfred E. Mann Foundation For Scientific Research |
Remote controls and ambulatory medical systems including the same
|
US20080194307A1
(en)
*
|
2007-02-13 |
2008-08-14 |
Jeff Sanger |
Sports-based game of chance
|
AU2008310735B2
(en)
|
2007-10-12 |
2013-09-12 |
Takeda Pharmaceutical Company Limited |
Methods of treating gastrointestinal disorders independent of the intake of food
|
CN101980700A
(zh)
|
2008-02-20 |
2011-02-23 |
密苏里大学董事会 |
包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法
|
WO2009136398A2
(en)
*
|
2008-05-06 |
2009-11-12 |
Dexcel Ltd |
Stable benzimidazole formulation
|
DE102008045339A1
(de)
|
2008-09-01 |
2010-03-04 |
Stada Arzneimittel Ag |
Pharmazeutisches Pellet
|
KR20110079641A
(ko)
|
2008-09-09 |
2011-07-07 |
아스트라제네카 아베 |
제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
|
US8828953B2
(en)
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
US9901551B2
(en)
*
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
MX2011013467A
(es)
|
2009-06-25 |
2012-02-13 |
Astrazeneca Ab |
Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
|
WO2011080502A2
(en)
|
2009-12-29 |
2011-07-07 |
Orexo Ab |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
EP2519229A2
(en)
|
2009-12-29 |
2012-11-07 |
Novartis AG |
New pharmaceutical dosage form for the treatment of gastric acid-related disorders
|
FR2959509B1
(fr)
|
2010-05-03 |
2012-07-13 |
Prod Chim Auxiliaires Et De Synthese |
Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
|
CN102762198A
(zh)
*
|
2010-05-15 |
2012-10-31 |
欢腾生命科学有限公司 |
多单元组合物
|
IT1401284B1
(it)
|
2010-08-06 |
2013-07-18 |
Valpharma S P A |
Nuove formulazioni farmaceutiche idonee per la somministrazione orale di esomeprazolo magnesio diidrato, in forma di compresse mups (multi unit pellets system).
|
JP2013540156A
(ja)
|
2010-10-19 |
2013-10-31 |
エルセリクス セラピューティクス インコーポレイテッド |
化学感覚受容体リガンドに基づく治療法
|
PT2773348T
(pt)
*
|
2011-11-02 |
2018-04-16 |
Esteve Labor Dr |
Composição farmacêutica de omeprazol
|
CN104519888A
(zh)
|
2011-12-28 |
2015-04-15 |
波曾公司 |
用于递送奥美拉唑和乙酰水杨酸的改良组合物和方法
|
CN103040774B
(zh)
*
|
2012-11-30 |
2015-03-04 |
上海信谊万象药业股份有限公司 |
埃索美拉唑镁肠溶片中埃索美拉唑镁的制粒包衣工艺
|
CN103044400A
(zh)
*
|
2012-12-21 |
2013-04-17 |
北京华禧联合科技发展有限公司 |
埃索美拉唑镁盐及其制备方法
|
JP5934835B2
(ja)
*
|
2013-03-08 |
2016-06-15 |
富士フイルム株式会社 |
腸溶性細粒及び医薬組成物
|
EP2933002A1
(en)
|
2014-04-11 |
2015-10-21 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Pharmaceutical combinations of dabigatran and proton pump inhibitors
|
WO2015155307A1
(en)
|
2014-04-11 |
2015-10-15 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
|
US20170182070A1
(en)
|
2014-10-08 |
2017-06-29 |
Mayne Pharma International Pty Ltd. |
Controlled Release Doxycycline
|
US10105322B2
(en)
*
|
2014-10-08 |
2018-10-23 |
Synthetic Biologics, Inc. |
Beta-lactamase formulations and uses thereof
|
CN104586809A
(zh)
*
|
2015-01-08 |
2015-05-06 |
浙江亚太药业股份有限公司 |
一种埃索美拉唑镁微丸肠溶片及制备方法
|
US11103517B2
(en)
|
2015-04-07 |
2021-08-31 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical compositions for minocycline
|
EP3288556A4
(en)
|
2015-04-29 |
2018-09-19 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
CA3033065A1
(en)
|
2016-08-11 |
2018-02-15 |
Adamis Pharmaceuticals Corporation |
Drug compositions
|
US10946002B2
(en)
*
|
2016-10-06 |
2021-03-16 |
Jubilant Generics Limited |
Pharmaceutical suspension dosage form of benzimidazole compounds and process of preparation thereof
|
KR101877350B1
(ko)
|
2016-10-28 |
2018-08-09 |
한미약품 주식회사 |
에스오메프라졸 함유 복합 캡슐제 및 그 제조방법
|
CZ2017315A3
(cs)
|
2017-06-02 |
2018-12-12 |
Zentiva, K.S. |
Dávkovací jednotka s PPI (inhibitory protonové pumpy)
|
EP3720844A4
(en)
|
2017-12-08 |
2021-08-11 |
Adamis Pharmaceuticals Corporation |
MEDICINAL COMPOSITIONS
|
KR102080023B1
(ko)
|
2018-01-29 |
2020-02-21 |
주식회사 종근당 |
에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
|
KR102006777B1
(ko)
|
2018-01-29 |
2019-10-08 |
주식회사 종근당 |
에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
|
WO2020040438A1
(ko)
|
2018-08-23 |
2020-02-27 |
주식회사 종근당 |
에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
|
JP2022541948A
(ja)
|
2019-07-26 |
2022-09-28 |
チョン クン ダン ファーマシューティカル コーポレイション |
エソメプラゾール及び炭酸水素ナトリウムを含む安定した薬学的組成物
|
WO2021153525A1
(ja)
|
2020-01-27 |
2021-08-05 |
東和薬品株式会社 |
エソメプラゾール経口製剤およびその製造方法
|
KR102573842B1
(ko)
|
2020-02-21 |
2023-09-01 |
주식회사 종근당 |
방출특성이 우수한 에스오메프라졸 및 탄산수소나트륨의 약제학적 조성물
|
KR20210012881A
(ko)
|
2020-02-28 |
2021-02-03 |
주식회사 종근당 |
에스오메프라졸 및 탄산수소나트륨을 포함하는 우수한 방출특성을 갖는 약제학적 제제
|
CN114569579B
(zh)
|
2020-12-02 |
2023-10-31 |
丽珠医药集团股份有限公司 |
肠溶微丸、其制备方法和包含它的制剂
|
CN115120569B
(zh)
*
|
2022-07-07 |
2023-11-28 |
江苏中邦制药有限公司 |
一种去除微丸间静电的方法
|
KR20240030479A
(ko)
|
2022-08-31 |
2024-03-07 |
한올바이오파마주식회사 |
에스오메프라졸 및 제산제를 포함하는 약제학적 제제 및 이의 제조방법
|